Transformation of Physical DVHs to Radiobiologically Equivalent Ones in Hypofractionated Radiotherapy Analyzing Dosimetric and Clinical Parameters: A Practical Approach for Routine Clinical Practice in Radiation Oncology
Table 2
Patients’ characteristics and EORTC/RTOG acute toxicity for prostate (rectal toxicity) and breast (skin toxicity) cancer.
Prostate cancer ()
Median age (range)
70 (63–78)
T1 (%)
19/50 (38%)
T2 (%)
31/50 (62%)
Mean PSA (range)
8.142 (6.5–9.9)
EORTC/RTOG rectal acute toxicity
Grade 0
Grade 1
Grade 2
Grade 3
Grade 4
Increased frequency or change in quality of bowel habits not requiring medication/rectal discomfort not requiring analgesics
Diarrhea requiring parasympatholytic drugs/mucous discharge not necessitating sanitary pads/rectal or abdominal pain requiring analgesics
Acute or subacute obstruction, fistula, or perforation; GI bleeding requiring transfusion; abdominal pain or tenesmus requiring tube decompression or bowel diversion
(%)
35/50 (70%)
14/50 (28%)
1/50 (2%)
— (0%)
— (0%)
Breast cancer ()
Median age (range)
56 (44–72)
T1 (%)
35/50 (70%)
T2 (%)
15/50 (30%)
Menopausal (%)
43/50 (86%)
EORTC/RTOG acute skin toxicity
Grade 0
Grade 1
Grade 2
Grade 3
Grade 4
Follicular, faint, or dull erythema/epilation/dry desquamation/decreased sweating
Tender or bright erythema, patchy moist desquamation/moderate edema
Confluent, moist desquamation other than skin folds, and pitting edema
